Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > TOP STORIES
TOP STORIES
-
BUSINESS Big 4 Wholesalers Suffer 80% Drop in Operating Profit on COVID, Discount, Price Battle: 1H 2020
November 9, 2020
-
ORGANIZATION JPMA Sorts Out Challenges for Remote Clinical Trial to Promote Its Introduction in Japan
November 9, 2020
-
BUSINESS Expert Panel Delivers Harsh Verdict on Aducanumab, FDA Decision Due by March 7
November 9, 2020
-
BUSINESS 1st Half Sales of 7 Major Japan Drug Makers Skid 1.9% on Price Cuts, COVID-19; Core Products Brisk
November 6, 2020
-
BUSINESS In a Digital Push, Takeda Encouraging Sales Reps to Gain IT Qualification: Japan Chief
November 5, 2020
-
REGULATORY Ryukaikon Confab Finally Set for November 24; Can Japan Improve Drug Distribution Environment Again?
November 4, 2020
-
BUSINESS Ex-Merck Serono President Leo Lee Becomes Japan Chief of Novartis
November 2, 2020
-
BUSINESS Emerging from Repeated Price Cuts, Opdivo’s Japan Sales Could Top 100 Billion Yen in FY2020
October 30, 2020
-
REGULATORY Japan to Receive 50 Million Doses of Moderna COVID-19 Vaccines via Takeda
October 29, 2020
-
BUSINESS GSK Might Adjust Shipments for Cervarix as Surge in Demand Expected
October 29, 2020
-
BUSINESS Copay Rose for Some Patients as Leuplin Issue Triggered Shortage of 6-Month Depot: HCPs
October 28, 2020
-
BUSINESS Pharma’s Half-Year Earnings Season in Full Swing from This Week
October 27, 2020
-
BUSINESS Ono Says Honjo’s 22.6 billion Yen Claim Groundless, No Agreement Reached on 40% Opdivo Fee Proposal
October 27, 2020
-
REGULATORY PM Suga Vows to Work towards Annual Price Revisions: Diet Policy Speech
October 27, 2020
-
REGULATORY 1st Working Group Meeting for Prioritization of “Stable Supply Medicines” Set for Early November
October 26, 2020
-
BUSINESS Novartis Looks to Solidify Presence in Multiple Sclerosis Arena with Mayzent, then Ofatumumab
October 23, 2020
-
BUSINESS GSK Sets Up Oncology Biz Unit in Japan; Multiple Late-Stage Assets in Pipeline
October 22, 2020
-
REGULATORY PMDA Sees Studies on Preventive Effect as a “Must” for Coronavirus Vaccines: Official
October 21, 2020
-
BUSINESS Pfizer, BioNTech Begin Japan PI/II Study for COVID-19 Vaccine
October 21, 2020
-
BUSINESS LEO Pharma’s Atopic Dermatitis Program Lags as PMDA Requests Japanese Data, but Growth Goal Intact
October 20, 2020
ページ
Japan’s pharmaceutical industry could be on the verge of gaining a stronger voice in the Central Social Insurance Medical Council…
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…